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Myxoinflammatory Fibroblastic Sarcoma in the Chest Wall
Kyoung Shik Narm, M.D.1, In Kyu Park, M.D., Ph.D.2, Mi Kyung Bae, M.D.1, Gi Jeong Kim, M.D.3
Myxoinflammatory fibroblastic sarcoma (MIFS) is a recently defined rare tumor. It is mainly found in the upper and 
lower extremities of adults. Due to its high local recurrence rate and low metastatic rate, it is classified as a low 
grade-malignancy. Accurate diagnosis and early, wide excision are important for prognosis. Herein, we report a 
case of MIFS in a 35-year-old male patient that presented in an unusual location, the left chest wall. To our 
knowledge, this is the first reported case of MIFS in Korea and the second case to be reported within the global 
scientific literature involving the chest wall.
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CASE REPORT
A 35-year-old man visited our hospital presenting with a 
palpable mass on his left lateral chest wall, which was mov-
able, rubbery, and non-tender. A gun biopsy assisted by ultra-
sonography was performed, but failed to confirm a specific 
diagnosis; therefore, we performed a local excision. The mass 
was 3×2×1 cm, non-adhesive, round, and pink; the cut sec-
tions evidenced well-demarcated, gray-white gelatinous mass-
es. A microscopic examination revealed a tumor in the sub-
cutaneous tissues without invasion to the adjacent structures 
(Fig. 1). The specimen exhibited a mixture of myxoid, hya-
line, and inflammatory zones (Fig. 2). Scattered and enlarged 
tumor cells, each with a large eosinophilic nucleus resembling 
a virocyte, were observed, consistent with a diagnosis of 
myxoinflammatory fibroblastic sarcoma (MIFS) (Fig. 3A, B). 
An immunohistochemical study revealed that the tumor cells 
had a strong positivity for vimentin and focal positivity for 
CD34 and CD68, confirming the diagnosis of MIFS.
A microscopic histological analysis of the specimen re-
vealed that the mass was abutting to the resection margin in 
a series of multifocal areas. Thus, an additional wide excision 
was advised for an adequate tumor-free margin. On combined 
positron emission tomography and computed tomography, flu-
oro-2-deoxy-D-glucose uptake was increased at the left chest 
wall, probably due to a previous procedure; multiple nodules 
were also observed in the right lung, suggesting possible lung 
metastasis.
After administering general anesthesia and single-lung ven-
tilation, a wedge resection of the right upper lung, including 
the nodules, was performed under video-assisted thoraco-
scopic surgery conditions. The frozen sectional diagnosis of 
the lung nodules confirmed a benign pneumocyte hyperplasia. 
Subsequently, a wide left chest wall excision was performed, 
including partial resections of the 5th, 6th, and 7th ribs. The 
tumor free margin of the subcutaneous and muscle layers was 
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Fig. 1. A lower-power view of the inflammatory myxohyaline tu-
mor illustrating a mixture of myxoid, hyaline, and inflammatory
zones (H&E, ×12).
Fig. 2. An admixture of myxoid, hyaline, and inflammatory zones 
in an inflammatory myxohyaline tumor. Note the transition between 
myxoid and hyaline zones (H&E, ×100).
Fig. 3. (A) A higher-magnification view of cells with smudgy nuclei in a myxoid zone of an inflammatory myxohyaline tumor (H&E, ×200).
(B) An enlarged tumor cell with a large eosinophilic nucleus resembling a virocyte in an inflammatory myxohyaline tumor (H&E, ×400).
4 cm, and the skin margin was 2 cm. After the procedure, 
there was no gross evidence of a residual tumor. The chest 
wall was reconstructed with polypropylene mesh (Marlex, CR 
Bard Inc., Billerica, MA, USA) and bone cement. The patient 
was discharged on postoperative day 10.
DISCUSSION
MIFS, or acral MIFS, is a low-grade, malignant tumor that 
has only recently been defined pathologically. About 200 cas-
es have been reported since it was first described in 1998 by 
Montgomery et al. [1].
In 80% of cases, the lesion involves the subcutaneous tis-
sues of the hands or feet [2], but it can be also be found on 
the elbows, thighs, or shoulders; thus the term “acral” was 
dropped in the 2002 World Health Organization classification 
[3].
Clinically, MIFS usually presents as a slow-growing, soli-
tary, and painless mass that can sometimes infiltrate ex-
tensively into the surrounding soft tissues. Grossly, it is usu-
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ally visible as an ill-defined, multinodular mass, with myxoid 
areas, within the subcutaneous tissue, and has an irregular 
border and invasive margin [1,4]. Necrosis or hemorrhage 
may also occur. The tumors are 1−8 cm in size and dis-
charge a clear, jelly-like substance when compressed [4].
The simple X-ray imaging of the affected area did not pro-
vide any specific findings. A magnetic resonance imaging al-
so provided no pathognomonic patterns because of the mass’ 
varied histological composition; however, the images did ex-
hibit low signal intensity on the T1-weighted image and high 
signal intensity on the T2-weighed image.
Histologically, the mass was composed of dense, mixed 
acute and chronic inflammatory cells, and the hypocellular 
area was composed of hyaline and myxoid zones. 
Characteristic ganglion-like, lipoblast-like, and polygonal spin-
dle cells that contained bizarrely shaped nuclei and in-
clusion-like nucleoli were present in an abundant eosinophilic 
cytoplasm. These cells were derived from the modified fibro-
blast cells and chronic inflammatory cells. A mitotic division 
was generally rare, and necrosis was often evident. Upon the 
immunohistochemical study, vimentin was always positive, 
CD68 and CD34 exhibited variable positivity, and HMB45 
and CD45 were always negative [4]. 
The differential diagnosis can be broad and varied depend-
ing on whether the inflammatory, myxoid, or bizarre atypical 
component predominates within the lesion. Tenosynovitis, 
ganglion cyst, and myxoma (for the inflammatory and benign 
entities), and myxoid malignant fibrous histiocytoma, myxoid 
liposarcoma, and epithelioid sarcoma (for the malignant tu-
mors) are the main components of the histopathological dif-
ferential diagnosis of a giant cell tumor in the tendon sheath 
or of a myxoid origin [2,5]. Because of the difficulty of an 
accurate diagnosis from the lesion’s clinical presentation or 
radiological characteristics, the diagnosis is often delayed and 
a surgical excision is more likely to be suboptimal. 
The local recurrence rate of the tumor is high (range, 22% 
to 67%) when a local excision alone has been performed, 
usually being reported between 3 months and 5 years post-
operatively [4]. The distant metastasis rate is low (6.5%); 
however, cases have reported metastasis to the lung, neck, 
and skull [6,7]. One tumor-related death has been reported 
[6].
Although the treatment process has not been well-defined, 
a complete excision with clear margins is recommended. 
Postoperative radiotherapy may be a good additional therapy 
for patients who have a large tumor or a positive resection 
margin [2,8]. Some papers also report chemotherapy as an 
option [4].
There has only been one other reported case of MIFS in-
volving the chest wall. Premalata et al. [5] reported upon a 
MIFS of the upper back, over the scapula. They performed a 
wide excision of the tumor, without rib resection, and re-
ported no recurrence within 10 months after surgery. We per-
formed a wider local excision with a tumor free margin of 4 
cm, including an adjacent rib resection and the reconstruction 
of the chest wall, in accordance with the guidelines for a ma-
lignant tumor of the chest wall.
In summary, MIFS is a very rare tumor that predominantly 
affects the distal extremities. It has not been previously de-
scribed in the Korean literature. We report the first case of 
MIFS in Korea, and the second such tumor to be described 
in the chest wall. The patient underwent a wide local ex-
cision and a chest wall reconstruction.
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